Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04730661
Other study ID # 2020/0339/HP
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 21, 2020
Est. completion date December 28, 2021

Study information

Verified date January 2021
Source University Hospital, Rouen
Contact ELISE ARTAUD-MACARI, MD
Phone +33232885992
Email elise.artaud-macari@chu-rouen.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

As part of the Coronavirus Infectious Disease 2019 (COVID19) pandemic, the hospital care system is facing a major strain. Patients with SARS-Cov2 (severe acute respiratory syndrome coronavirus 2 ) infection can worsen very quickly, possibly presenting, within hours, severe respiratory failure requiring urgent specialized care. Therefore, it is essential to develop emergency assessment tools to assess relevant criteria to decide which patients must be kept under hospital monitoring and which patients can be treated on outpatient care. The aim of this study is to assess the efficacy of STST in the decision to hospitalize patients consulting emergency department for a SARS-Cov2 infection. The investigators wish to show that the addition of this test to the usual hospitalization criteria reduces the proportion of patients hospitalized 48 hours after their first visit to the emergency department.


Recruitment information / eligibility

Status Recruiting
Enrollment 146
Est. completion date December 28, 2021
Est. primary completion date December 21, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult (=18 years old) - Admit to emergency department for suspected SARS-Cov2 infection - SARS-CoV2 infection confirmed by Real Time Polymerase Chain Reaction (RT - PCR) before the first discharge of emergency department - Patient affiliated or beneficiary of a health care insurance - Effective contraception in women of childbearing age. For postmenopausal women, amenorrhea for at least 12 months before the inclusion visit Exclusion Criteria: - Patient presenting criteria for admission to intensive care: signs of acute respiratory distress , respiratory rate> 30 / min, oxygen dependence > 6L / min on face mask for an SpO2 = 95% or an arterial oxygen pressure >8kPa, neurological disorders, systolic blood pressure (SBP) <90mmHg despite fluid resuscitation, lactates> 2mmol / L, bradycardia, or heart rate disorders - Patient with SpO2 <90% in spontaneous ventilation in room air at rest - Patient with functional impairment or deterioration of the general condition leading to the inability to perform STST - Patient with a resting SBP> 180 mmHg or resting diastolic blood pressure (DBP)> 100 mmHg or resting heart rate (HR)> 120 / min - Patient with decompensated or unbalanced cardiac pathology - Patient previously included in the study following a previous admission to emergency department - Patient deprived of liberty, unable to consent freely - Patient non affiliated or beneficiary of a health care insurance

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Sit to stand test
The sit to stand test (or STST) is a test consisting of performing as many sit-to-stand tests as possible in one minute, from a chair without armrests. We note before and during this test, the SpO2 (pulsed oxygen saturation) (rest value and minimum value during exercise), heart rate (HR), dyspnea on the modified Borg scale as well as the number of chair lifts performed. completely and minimum SpO2 during the recovery phase. The possible results from this one-minute test are as follows: If SpO2 <90% or appearance of signs of respiratory distress: Immediate stop of the test and hospitalization SpO2 <90% or decrease in SpO2 = 4% during the test or during the recovery period: Hospitalization SpO2 =90% and no decrease in SpO2 = 4% during the test or during the recovery period which will be 3 minutes maximum: discharge.

Locations

Country Name City State
France Rouen university hospital Rouen

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Rouen

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of late hospitalizations, within 48 hours of first discharge from emergency department, and motivated by worsening symptoms secondary to SARS-Cov2 infection. 7 days
Secondary Proportion of immediate hospitalizations after the 1st admission at emergency department. 7 days
Secondary Proportion of adverse events related to SARS-Cov2 infection within 7 days of patient inclusion. The adverse events identified are:
medical consultation,
readmission to the emergency department,
hospitalization,
hospitalization in intensive care unit,
death.
7 days
Secondary Establish the correlation between the number of chair rises performed on STST and the occurrence of an adverse event. The adverse events identified are:
medical consultation,
readmission to the emergency department,
hospitalization,
hospitalization in intensive care unit,
death.
7 days
Secondary Correlation between SpO2 and the occurrence of an adverse event the difference between the measurement of SpO2 before and after STST will be used to establish the correlation between this difference and the occurrence of an adverse event. 7 days
Secondary Correlation between heart rate (HR) and the occurrence of an adverse event the difference between the measurement of HR before and after STST will be used to establish the correlation between this difference and the occurrence of an adverse event. 7 days
Secondary Correlation between dyspnea score and the occurrence of an adverse event the difference between the measurement of dyspnea score before and after STST will be used to establish the correlation between this difference and the occurrence of an adverse event. 7 days
See also
  Status Clinical Trial Phase
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546776 - COVID-19 Persistence in Stool
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04542915 - COVID-19-Related Health and Practices Among Dental Hygienists
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Recruiting NCT04615052 - Home-based Exercise in COVID-19 Survivors N/A
Enrolling by invitation NCT04659486 - Adolescents With COVID-19/MIS-C at HCFMUSP N/A
Recruiting NCT04885452 - Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.
Completed NCT05063812 - Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19
Completed NCT04516928 - Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel
Completed NCT04530357 - Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine Phase 1/Phase 2
Recruiting NCT04565782 - Corona Virus Infection Among Liver Transplant Recipients
Completed NCT04550390 - Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19
Completed NCT04733625 - The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection N/A
Active, not recruiting NCT04517136 - Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions
Recruiting NCT04476680 - Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion N/A
Completed NCT04514874 - Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020
Completed NCT04839913 - Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Unicentric, Regional Study
Terminated NCT04606563 - Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? Phase 3
Completed NCT05234359 - The CHILD Cohort COVID-19 Add-On Study